The organizations launched the center with a $20 million CZI grant to build on the success of the first personalized CRISPR base-editing therapy.

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.

The trial will test the drug in metastatic castration-resistant prostate cancer patients with low alkaline phosphatase levels, a marker of less advanced disease.

NEW YORK – RedHill Biopharma has begun recruiting patients with metastatic castration-resistant prostate cancer to a Phase II trial testing the combination of opaganib, its small molecule sphingosine ...

NEW YORK – Ensem Therapeutics on Tuesday said it dosed the first patient in a Phase I/II trial of the mutant-selective PI3kα inhibitor ETX-636 in patients with solid tumors. ETX-636 is designed to ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

NEW YORK – Neurogene this week said it has taken steps to begin a registrational trial to evaluate NGN-401, its investigational gene therapy for Rett syndrome, after reaching an agreement with the US ...

NEW YORK – A new law in Texas could pave the way for more community cancer practices to provide CAR T-cell therapy. At least that's the goal, according to Brooks Landgraf, a Republican representative ...

Precision Medicine Online and My Gene Counsel have partnered since 2019 on the "Genetic Testing Challenges" series to highlight real-world issues medical professionals are encountering as genetic ...

NEW YORK – In a safety communication earlier this week, the US Food and Drug Administration said it is investigating the risk of fatal acute liver failure with Sarepta Therapeutics' Elevidys ...

NEW YORK – Allarity Therapeutics has begun dosing patients in a Phase II trial studying its dual PARP and WNT pathway inhibitor stenoparib in patients with advanced, recurrent, platinum-resistant or ...